Snehal Patel Acquires 2,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 2,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was bought at an average cost of $11.97 per share, with a total value of $23,940.00. Following the purchase, the chief executive officer now owns 5,543,702 shares in the company, valued at approximately $66,358,112.94. This represents a 0.04 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Snehal Patel also recently made the following trade(s):

• On Monday, December 30th, Snehal Patel acquired 3,200 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $11.12 per share, with a total value of $35,584.00.

Greenwich LifeSciences Stock Up 5.3 %

GLSI opened at $13.81 on Wednesday. The business’s fifty day simple moving average is $13.18 and its 200 day simple moving average is $14.14. Greenwich LifeSciences, Inc. has a 52 week low of $8.00 and a 52 week high of $21.44. The stock has a market cap of $181.53 million, a PE ratio of -17.26 and a beta of 1.66.

Hedge Funds Weigh In On Greenwich LifeSciences

Several institutional investors have recently modified their holdings of the company. Rhumbline Advisers purchased a new stake in Greenwich LifeSciences in the second quarter worth approximately $117,000. Barclays PLC lifted its holdings in shares of Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after acquiring an additional 6,538 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $264,000. Garden State Investment Advisory Services LLC bought a new position in shares of Greenwich LifeSciences during the 3rd quarter valued at $253,000. Finally, State Street Corp raised its position in Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after purchasing an additional 3,005 shares during the period. 4.16% of the stock is currently owned by institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.